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The delta isoform of the p110 catalytic subunit (p110δ) of phosphoinositide 3-kinase
is expressed primarily in hematopoietic cells and plays an essential role in B-cell
development and function. Studies employing mice lacking a functional p110δ protein, as
well as the use of highly-selective chemical inhibitors of p110δ, have revealed that signaling
via p110δ-containing PI3K complexes (PI3Kδ) is critical for B-cell survival, migration, and
activation, functioning downstream of key receptors on B cells including the B-cell
antigen receptor, chemokine receptors, pro-survival receptors such as BAFF-R and the
IL-4 receptor, and co-stimulatory receptors such as CD40 and Toll-like receptors (TLRs).
Similarly, this PI3K isoform plays a key role in the survival, proliferation, and dissemination
of B-cell lymphomas. Herein we summarize studies showing that these processes can
be inhibited in vitro and in vivo by small molecule inhibitors of p110δ enzymatic activity,
and that these p110δ inhibitors have shown efficacy in clinical trials for the treatment
of several types of B-cell malignancies including chronic lymphocytic leukemia (CLL)
and non-Hodgkin lymphoma (NHL). PI3Kδ also plays a critical role in the activation,
proliferation, and tissue homing of self-reactive B cells that contribute to autoimmune
diseases, in particular innate-like B-cell populations such as marginal zone (MZ) B cells
and B-1 cells that have been strongly linked to autoimmunity. We discuss the potential
utility of p110δ inhibitors, either alone or in combination with B-cell depletion, for treating
autoimmune diseases such as lupus, rheumatoid arthritis, and type 1 diabetes. Because
PI3Kδ plays a major role in both B-cell-mediated autoimmune inflammation and B-cell
malignancies, PI3Kδ inhibitors may represent a promising therapeutic approach for treating
these diseases.
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THE ROLE OF PI3K SIGNALING IN B-CELL
DEVELOPMENT AND ACTIVATION
B cells play a critical role in immune system function and dys-
function (e.g., autoimmunity) by producing antibodies and by
acting as antigen-presenting cells (APCs) for T cells. Signaling
via phosphoinositide 3-kinase (PI3K) controls many essential B
cell functions and is therefore a promising target for prevent-
ing aberrant B cell activation. The class I PI3K enzymes consist
of a regulatory subunit that allows receptors to recruit PI3K to
the plasma membrane, and a catalytic subunit, which can then
phosphorylate phosphoinositide lipids on the 3′ position of their
inositol head group. The lipid second messengers generated by
PI3K, primarily phosphatidylinositol 3,4,5-trisphosphate (PIP3),
can recruit cytosolic signaling enzymes that contain pleckstrin
homology (PH) domains to the plasma membrane (Lemmon,
2008). The resulting formation of protein complexes facilitates
the activation of these signaling enzymes and brings them in
close proximity to their substrates. The PI3K “effectors” that
are recruited to the plasma membrane and activated in this
manner include signaling enzymes that control cell survival, acti-
vation growth, proliferation, and differentiation, as well as cell
motility, cell adhesion, and specialized processes such as phago-
cytosis (Okkenhaug and Vanhaesebroeck, 2003; Fruman, 2004).
The structure, enzymatic activity, and functions of the class I
PI3Ks have been described in detail in many excellent reviews
(Okkenhaug and Fruman, 2010; Vanhaesebroeck et al., 2010; So
and Fruman, 2012).
PI3K signaling is important for B-cell development (Fruman
et al., 1999; Suzuki et al., 1999; Clayton et al., 2002; Okkenhaug
et al., 2002) due its role in mediating the survival and dif-
ferentiation signals that are initiated by the pre-B-cell receptor
(Ramadani et al., 2010). In mature B cells, PI3K transduces sig-
nals from a wide variety of receptors that control nearly all
aspects of B-cell function. The survival of naïve B cells depends
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on constitutive low-level antigen-independent activation of PI3K
by the B-cell receptor (BCR) (Srinivasan et al., 2009) and by the
receptor for the cytokine B-cell activating factor (BAFF) (Henley
et al., 2008). These survival signals may be mediated, at least
in part, by the Akt protein kinase, a major downstream target
of PI3K signaling. Akt activates multiple pro-survival pathways
while inhibiting pro-apoptotic pathways.
The detection of foreign antigens by circulating B cells depends
on the ability of B cells to traffic into lymphoid organs and
migrate into the lymphoid follicles, where antigens are captured
and retained via multiple mechanisms (Batista and Harwood,
2009). The in vivo trafficking of B cells is directed by chemokines
such as CXCL13 and CCL21 as well as the lipid chemoattrac-
tant sphingosine 1-phosphate (S1P) (Stein and Nombela-Arrieta,
2005). The G protein-coupled receptors that bind chemoattrac-
tants activate PI3K, and this is critical for B cells to migrate
towards these stimuli. Once B cells encounter a foreign antigen,
which in the case of an infection will occur in the presence of
microbially-derived ligands for Toll-like receptors (TLRs), PI3K
signaling is essential for B-cell activation and proliferation as
well as the subsequent differentiation of B cells into antibody-
producing cells and the survival of memory B cells. As described
in detail elsewhere (Fruman, 2004), PI3K plays a central role in
the activation of many BCR signaling pathways. In particular,
PIP3-dependent activation of Bruton’s tyrosine kinase (Btk) is
crucial for the activation of phospholipase C-γ, an enzyme that
splits phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol
1,4,5-trisphosphate (IP3) and diacylglycerol, second messengers
that lead to increases in intracellular Ca2+, activation of multiple
protein kinase C isoforms, activation of the NF-κB and NF-AT
transcription factors, and activation of the Ras andRap1 GTPases,
the latter of which is a master regulator of cytoskeletal reorga-
nization and integrin-mediated adhesion. B-cell activation also
requires critical input from co-stimulatory receptors such as
CD40 and the IL-4 receptor, which transduce signals from helper
T cells, as well as TLRs, which are now thought of as a third sig-
nal for B-cell activation. CD40, the IL-4 receptor, and the main
TLRs expressed by B cells, TLR4 and TLR9, all signal via PI3K
(Figure 1). Not only does PI3K signaling act downstream of mul-
tiple receptors that drive different steps in the B-cell activation
process (Donahue and Fruman, 2004), it is also important for B
cells to bind to T cells so that they can act as APCs and elicit T
cell help in the form of CD40 ligand and IL-4 (Al-Alwan et al.,
2007).
FIGURE 1 | PI3Kδ is a central signaling enzyme that mediates the effects
of multiple receptors on B cells. PI3Kδ signaling is important for B-cell
survival, migration, and activation, functioning downstream of the B-cell
antigen receptor (BCR) and its co-receptor CD19, chemokine receptors
(CXCR5), and activating/co-stimulatory receptors such as CD40 and Toll-like
receptors (TLRs). Cytokines derived from lymphoid stromal cells (BAFF, IL-6)
and T cells (IL-4) that are essential for the expansion and survival of B cells
also require PI3Kδ for their actions and bind receptors that activate PI3Kδ.
The receptors depicted in this figure use a variety of kinases and adaptor
proteins to recruit PI3Kδ to the plasma membrane, where it can produce the
lipid second messenger PIP3. By binding to PH domain-containing proteins,
PIP3 promotes the activation of multiple signaling enzymes including PLCγ2
and Akt, both of which control key signaling networks. Note that the
connecting arrows may represent multiple intermediate signaling reactions.
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ISOFORM-SPECIFIC FUNCTIONS: A CRITICAL ROLE FOR
PI3Kδ IN B CELLS
There are four isoforms of class I PI3K catalytic subunits: p110α,
p110β, p110γ, and p110δ. Although these enzymes appear to have
identical substrate specificity, they clearly have distinct functions
in vivo, as revealed by the generation ofmouse strains in which the
genes encoding these different catalytic subunits have either been
disrupted or replaced by a catalytically inactive version (Rommel
et al., 2007; Vanhaesebroeck et al., 2010; So and Fruman, 2012).
This could be explained in part by differential expression or abun-
dance of the various isoforms in specific tissues. In particular,
p110γ and p110δ are expressed primarily in hematopoietic cells
and have important roles in the functions of both innate and
adaptive immune cells (Rommel et al., 2007). It is more diffi-
cult to explain how different PI3K isoforms can play distinct roles
within the same cell. Proposed models usually invoke preferential
recruitment of specific PI3K isoforms by different receptors or
to different membrane domains, which results in the formation
of distinct signaling complexes. This would presumably depend
on unique structural features of the different catalytic subunits
mediating specific interactions.
An intriguing finding is that p110α is important for the tonic
antigen-independent survival signals generated by the pre-BCR
and BCR whereas p110δ (but not p110α) is required for antigen-
dependent B-cell activation driven by the BCR (Ramadani et al.,
2010). These distinct roles of p110α and p110δ in homeo-
static versus antigen-induced BCR signaling could reflect differ-
ent mechanisms by which PI3K complexes are recruited to the
plasma membrane in resting versus activated B cells. The TC21
GTPase can directly bridge PI3K catalytic subunits to the non-
phosphorylated BCR immunoreceptor tyrosine-based activation
motifs (ITAMs) in resting B cells, thereby promoting homeostatic
PI3K signaling (Delgado et al., 2009). In contrast, antigen-
induced BCR clustering, and the resulting tyrosine kinase acti-
vation and ITAM phosphorylation, could abrogate the binding
of TC21 to the BCR and instead promote SH2-mediated binding
of PI3K to BCAP and CD19, scaffolding proteins that are tyro-
sine phosphorylated after BCR engagement. This model would
require that TC21 preferentially recruit p110α-containing PI3K
complexes whereas BCAP and CD19 preferentially recruit p110δ-
containing PI3K complexes. The finding that TC21 recruits p110δ
to the BCR in resting B cells (Delgado et al., 2009) does not
support this idea. However, this group did not assess whether
p110α was also recruited to the BCR by TC21. Thus, the basis
for the differential role of p110α and p110δ in homeostatic versus
antigen-initiated BCR signaling remains to be determined.
Although B cells express all four isoforms of the class I PI3K
p110 catalytic subunit (Bilancio et al., 2006), the p110δ isoform
has an essential and non-redundant role in many aspects of B
cell development and activation. In mice lacking a functional
p110δ protein, fewer mature circulating B cells (i.e., follicular
or B-2-B cells) are generated and the B cells that do develop
exhibit impaired chemokine-induced migration, BCR signaling,
and BCR-induced proliferation, which correlates with reduced
differentiation into antibody-producing cells and reduced serum
Ig levels both before and after immunization (Clayton et al., 2002;
Jou et al., 2002; Okkenhaug et al., 2002; Reif et al., 2004). This is in
contrast to knockout mice that lack the leukocyte-specific p110γ
catalytic subunit, which is often linked to signaling by G protein-
coupled receptors. Even though p110γ is normally expressed in
B cells, mice lacking p110γ have no apparent defects in B-cell
development or function (Sasaki et al., 2000). PI3Kδ also appears
to have a unique role in B-cell development and function in
humans. Several genetic polymorphisms in the p110δ gene have
been identified and a patient with a primary B-cell immunodefi-
ciency was found to have a missense mutation that resulted in an
aspartic acid to lysine replacement within the catalytic domain of
p110δ (Jou et al., 2006).
Highly selective small molecule inhibitors of p110δ such as
IC87114 (Sadhu et al., 2003a,b) and GS-1101, which is also
known as CAL-101 (Lannutti et al., 2011), allow inhibition of this
PI3K isoform both in vivo and in cells derived from normal ani-
mals. The inhibitory effects of IC87114 phenocopy the effects of
disrupting the p110δ gene or replacing it with a mutant version
that encodes a catalytically inactive form of p110δ (Okkenhaug
et al., 2002; Bilancio et al., 2006), supporting the idea that this
drug is highly selective for p110δ and can therefore be used as
a probe for p110δ function. The use of IC87114 has provided
significant insights into the role of p110δ in mature B cells.
In vitro, treating murine splenic B cells with IC87114 significantly
reduces IL-4-dependent B-cell survival, CXCL13-induced B-cell
migration, the ability of B cells to present antigens to T cells,
TLR-induced cytokine production, and both BCR- and TLR-
mediated B-cell activation, proliferation, differentiation, and
antibody secretion (Bilancio et al., 2006; Dil and Marshall, 2009;
Durand et al., 2009). IC87114 is also highly active in vivo and we
have shown that it can reduce antigen-specific antibody responses
in rodents (Durand et al., 2009).
THE ROLE OF PI3Kδ IN THE DEVELOPMENT, LOCALIZATION,
AND FUNCTION OF INNATE-LIKE B CELLS
The majority of B cells are conventional circulating B-2 cells.
However the marginal zone (MZ) B cells and B-1 subsets also play
important roles in host defense (Pillai et al., 2005; Baumgarth,
2011). B-1 cells are found in the peritoneal cavity and the spleen,
whereas MZ B cells reside near the marginal sinus of the spleen
where they are positioned to rapidly detect blood-borne micro-
bial infections. The Ig repertoires of B-1 and MZ B cells are
skewed toward the recognition of both microbial antigens and
self-antigens. So-called natural antibodies that are produced by
these B-cell subsets in the absence of any antigen stimulation (as
well as in germ-free mice) recognize cross-reactive epitopes on
Gram-positive bacteria, viruses, apoptotic cells, and oxidized low-
density lipoproteins (Ochsenbein et al., 1999; Zhang and Carroll,
2007; Binder et al., 2008). This provides protection against infec-
tion and also prevents inflammation by clearing oxidized lipids,
oxidized proteins, and apoptotic cells (Binder et al., 2008; Chou
et al., 2008; Baumgarth, 2011). In addition, exposure to TLR lig-
ands leads to a rapid increase in antibody production by B-1 and
MZ B cells. Hence, these B-cell subsets have been termed “innate-
like” B cells because of their constitutive production of protective
antibodies, their ability to mount rapid responses to infection,
and their localization to specific sites where they act as sentinels
of infection.
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A striking observation is that mice in which the gene encoding
the p110δ subunit has been disrupted or replaced with a catalyt-
ically inactive version have very few B-1 or MZ B cells (Clayton
et al., 2002; Okkenhaug et al., 2002). The reasons why the devel-
opment of these B-cell subsets is strongly dependent on p110δ
are not fully understood although PI3K-dependent Akt activa-
tion appears to be more important for the development of B-1
and MZ B cells than conventional B cells. Irradiated mice recon-
stituted with hematopoietic progenitors that lack both the Akt1
and Akt2 isoforms develop normal numbers of circulating B-2
cells but lack MZ B cells and have greatly reduced numbers of
B-1 cells (Calamito et al., 2010). The self-reactive nature of B-1
and MZ B cells has led to the idea that B-cell progenitors are
directed into these lineages by weak BCR signals initiated by
the binding of self-antigens, which could induce PI3K signal-
ing. Where and when this self-antigen encounter occurs is not
clear. B-1 cells are thought to arise from a unique population
of committed B-1 progenitor cells that retain self-renewal capac-
ity (Montecino-Rodriguez et al., 2006). MZ B cells arise from
transitional cells in the spleen that can give rise to either con-
ventional “follicular” B-2 cells or to MZ cells, a cell fate decision
in which Notch signaling promotes the MZ B cell fate (Pillai
and Cariappa, 2009). The role of PI3Kδ signaling in these cell
fate decisions is not known, although it has been proposed that
FOXO transcription factors, which are inhibited by PI3K-Akt sig-
naling, may oppose the effects of Notch signaling (Chen et al.,
2010).
Because B-1 and MZ B cells are nearly absent in mice lack-
ing a functional p110δ protein, we have used the p110δ-selective
inhibitor IC87114 to assess the role of this PI3K isoform in B-
1 and MZ B cells that had developed in normal wild-type mice.
These studies revealed a number of critical roles for p110δ activ-
ity in innate-like B cells (Durand et al., 2009). The localization of
innate-like B cells is critical for their ability to mount rapid T cell-
independent antibody responses against pathogens. For MZ B
cells, their location near the marginal sinus of the spleen positions
them to rapidly detect blood-borne pathogens. The retention of
MZ B cells in this region surrounding the B-cell follicles is main-
tained by integrin-mediated adhesion and by opposing chemoat-
tractant gradients established by the chemokine CXCL13, which
is produced by follicular dendritic cells within the B-cell folli-
cle and the lipid chemoattractant S1P, which is present at high
concentrations in the blood (Cinamon et al., 2004). In response
to TLR ligands as an indicator of infection or tissue damage,
MZ B cells can move into the B-cell follicles and may eventu-
ally exit the spleen and migrate to other tissues in response to
CXCL13 (Marino et al., 2008; Rubtsov et al., 2008). Similarly,
the mobilization of peritoneal B-1 cells to mucosal sites of infec-
tion is stimulated by TLR ligands and depends on a robust
migratory response to the chemokine CXCL13 (Ha et al., 2006).
Our in vitro studies showed that p110δ activity is important
for B-1 cells to migrate toward CXCL13 and for MZ B cells to
exhibit chemotactic responses to both CXCL13 and S1P (Durand
et al., 2009). In addition, CXCL13-stimulated adhesion of MZ
B cells to the integrin ligand ICAM-1 was reduced to below
basal level when these cells were treated with IC87114 (Durand
et al., 2009). Consistent with the finding that in vitro treatment
of MZ B cells with IC87114 inhibited both chemoattractant-
induced migration and adhesion, oral administration of IC87114
to mice dramatically reduced the number of MZ B cells sur-
rounding the B-cell follicles of the spleen, similar to what is
seen in mice lacking a functional p110δ protein (Durand et al.,
2009).
What are the molecular mechanisms by which PI3Kδ sig-
naling promotes the cell motility and cell adhesion that con-
trol the localization of MZ B cells? CXCL13- and S1P-induced
B-cell migration and adhesion are strongly dependent on acti-
vation of the Rap1 GTPase (Durand et al., 2006), a master
regulator of cytoskeletal organization, cell polarity, cell motil-
ity, and integrin activation (Bos, 2005). Our finding that p110δ
activity is required for CXCL13 and S1P to activate Rap1 in
B cells (Durand et al., 2009), combined with the observation
that Rap1b-deficient mice have greatly reduced numbers of MZ
B cells (Chen et al., 2008), suggests that p110δ-dependent acti-
vation of Rap1b is essential for the in vivo localization of MZ
B cells.
PI3Kδ signaling also plays an essential role in the activation
of innate-like B cells. Treating murine splenic MZ B cells or B-1
cells with either IC87114 or the pan-PI3K inhibitor LY294002
cause nearly complete inhibition of Akt phosphorylation that
is stimulated by CXCL13, by the TLR9 ligand CpG DNA, or
anti-Ig antibodies that cluster the BCR. IC87114 also inhibits
S1P-induced Akt phosphorylation in MZ B cells (neither B-1
nor B-2 cells respond well to S1P). These findings suggest that
p110δ is the main PI3K isoform linking the BCR, TLR9, and
the receptors for CXCL13 and S1P to activation of the Akt pro-
survival kinase in innate-like B cells. This is somewhat surprising
with regard to chemoattractant signaling since G protein-coupled
receptors such as those that bind CXCL13 and S1P are often
coupled to PI3Kγ. PI3Kγ is expressed in B cells (Bilancio et al.,
2006), although this analysis has not been carried out on iso-
lated B-1 or MZ B cell populations. However, mice lacking
p110γ have no apparent defects in B-cell development or func-
tion (Sasaki et al., 2000), suggesting that p110δ substitutes for
p110γ in linking G protein-coupled receptors to the PI3K/Akt
pathway in B cells. Befitting their role as sentinels that provide
early detection and protection from infection, innate-like B cells
are most frequently activated in a polyclonal manner by TLR lig-
ands. The ability of the TLR ligands lipopolysaccharide (LPS)
and CpG DNA to induce the proliferation of B-1 and MZ B
cells and to increase antibody secretion by purified splenic MZ
cells or peritoneal B-1 cells is substantially reduced in the pres-
ence of the p110δ inhibitor IC87114 (Durand et al., 2009). Recent
work has suggested the TLRs may activate p110γ in myeloid cells
(Schmid et al., 2011) but its contribution to TLR-induced acti-
vation of innate-like B cells has not been assessed. Nevertheless,
it is clear that p110δ activity is critical for the activation of
innate-like B cell populations by chemokines, antigens, and TLR
ligands.
Taken together, these data suggest that p110δ inhibitors such
as IC87114 may be useful for inhibiting the in vivo trafficking,
localization, and activation ofMZ B cells and B-1 cells, innate-like
B-cell populations that have been strongly implicated in a variety
of autoimmune diseases.
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PI3Kδ AS A TARGET FOR TREATING B CELL-MEDIATED
AUTOIMMUNE DISEASES
Autoimmune inflammatory diseases such as rheumatoid arthri-
tis, systemic lupus erythematosus (SLE), and type 1 diabetes affect
millions of people worldwide. The aging population, especially in
the developed world, as well as complex environmental factors,
has contributed to a significant increase in the number of patients
requiring treatment. Although there have been dramatic advances
in the development of biological treatments in the form of anti-
bodies and recombinant proteins, not all patients experience
effective disease management. Hence there continues to be a need
for new treatment approaches that provide effective long-term
protection from disease progression with minimal side effects,
simple delivery, and reasonable cost.
THE ROLE OF B CELLS IN CHRONIC AUTOIMMUNE INFLAMMATORY
DISEASES
B cells play a major role in a number of autoimmune dis-
eases via their production of autoantibodies, their ability to act
as APCs that present self-antigens to autoreactive T cells, and
their production of pro-inflammatory cytokines (Murakami and
Honjo, 1997; Fields and Erikson, 2003; Martin and Chan, 2006;
Shlomchik, 2008; Yanaba et al., 2008). The role of B cells in
the pathogenesis of rheumatoid arthritis, type 1 diabetes, multi-
ple sclerosis, SLE, and several other autoimmune inflammatory
diseases has been described in detail elsewhere (Yanaba et al.,
2008).
Aberrant B-cell activation and polyclonal antibody produc-
tion can occur when there are defects in negative regulators of
BCR signaling such as the Shp1 tyrosine phosphatase. In mice,
the loss of Shp1 only in B cells is sufficient to cause an SLE-like
disease (Pao et al., 2007). Viral and bacterial infections may also
trigger autoimmunity by causing polyclonal activation of B cells
via TLRs. In contrast to polyclonal B-cell activation, the loss of
B-cell tolerance due either to intrinsic defects or to aberrant T-cell
activation can result in the production of characteristic autoanti-
bodies, for example the “rheumatoid factor” anti-IgG antibodies
that are associated with rheumatoid arthritis. Autoantibodies
can greatly amplify inflammatory responses and thereby play an
important role in promoting tissue damage. Immune complexes
containing IgM or IgG autoantibodies can initiate complement-
mediated inflammation and can activate inflammatory cells by
binding to Fc receptors. The formation of large immune com-
plexes can also cause blockages that lead to glomerulonephritis
or thrombosis (Lipsky, 2001). Finally, autoantibodies that bind to
host cells may promote antibody-dependent cellular cytotoxicity
carried out by NK cells or macrophages.
More recent data have shown that B cells can also initiate and
amplify autoimmune disease via their ability to present antigens
to T cells. This has been demonstrated convincingly in the non-
obese diabetic (NOD)mouse model of spontaneous autoimmune
type 1 diabetes. NOD mice that lack B cells (NOD μMT mice)
do not develop diabetes (Serreze et al., 1996). However, NOD
mice in which B cells are present but cannot secrete antibod-
ies develop diabetes to the same extent as wild-type NOD mice
(Wong et al., 2004). This suggests that the major role for B cells in
autoimmune diabetes is as APCs. Consistent with this conclusion,
B cells are required for the proliferation of diabetogenic T cells in
NOD mice (Katz et al., 1993; Serreze et al., 1996; Falcone et al.,
1998; Noorchashm et al., 1999a; Tian et al., 2006; Marino and
Grey, 2008) and for the activation and survival of CD8+ T cells
that infiltrate the pancreas and attack the insulin-producing beta
cells (Brodie et al., 2008). The hyperactivated B cells present
in autoimmune animals and patients are highly effective APCs
because they express elevated levels of MHC proteins and the
T cell co-stimulatory molecules CD80 and CD86 on their surface.
Cytokine production by B cells may also contribute to the
progressive amplification of autoimmune processes. Activated
B cells can produce pro-inflammatory cytokines such as IL-6
(Shlomchik, 2008; Yanaba et al., 2008). Moreover, in chronic
inflammatory autoimmune diseases such as rheumatoid arthri-
tis, lymphotoxin-β produced by B cells promotes the formation
of ectopic GCs within the inflamed tissue (Takemura et al., 2001;
Bugatti et al., 2007). Activated B cells that enter these germinal
centers undergo clonal expansion, somatic hypermutation, and
affinity maturation, leading to increased production of higher
affinity self-reactive antibodies (Kim and Berek, 2000).
THE ROLE OF INNATE-LIKE B CELLS IN AUTOIMMUNITY
In a number of mouse models of autoimmune inflammatory dis-
eases such as rheumatoid arthritis and SLE, disease progression
is strongly associated with an expansion of B-1 and MZ B cell
populations and a corresponding increase in the production of
self-reactive antibodies that may contribute to the autoimmune
pathology (Batten et al., 2000; Duan andMorel, 2006; Ishida et al.,
2006; Bugatti et al., 2007; Pao et al., 2007; Marino et al., 2008).
The role of innate-like B cells in autoimmunity has been char-
acterized extensively in mouse models of autoimmune diabetes
that closely resemble autoimmune type 1 diabetes in humans. In
type 1 diabetes, T cells specific for pancreatic beta cells become
activated and infiltrate the islets of Langerhans. CD8+ cyto-
toxic T cells directly kill beta cells while pathogenic CD4+ TH1
cells recruit macrophages that produce inflammatory mediators
such as IL-1β, TNF-α, and nitric oxide, which combine to cause
beta cell dysfunction and death. The net result is progressive
destruction of the beta cells, leading to insulin deficiency and
hyperglycemia. At least in the NOD mouse model of sponta-
neous autoimmune diabetes, innate-like B cells appear to play an
important role in disease progression. NOD mice have increased
numbers of MZ B cells (Marino et al., 2008), a phenotype that
maps to the Idd9/11 diabetes susceptibility locus (Rolf et al.,
2005). Prior to the onset of diabetes in NOD mice, activated
MZ B cells accumulate in the pancreatic lymph node (Marino
et al., 2008), the main site of activation of diabetogenic T cells.
MZ B cells are efficient APCs (Attanavanich and Kearney, 2004),
express T cell co-stimulatory molecules when activated (Oliver
et al., 1999; Wither et al., 2000; Marino et al., 2008), and can
effectively present beta cell antigens to self-reactive T cells from
NOD mice and induce their proliferation (Marino et al., 2008).
Consistent with a role for MZ B cells in the development of
autoimmune diabetes, the somewhat selective depletion of MZ B
cells with antibodies to CD21/CD35 reduces the disease incidence
in a mouse model (Noorchashm et al., 1999b). B-1 cells may also
promote the autoimmune destruction of islet cells. B-1 cells are
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found primarily in the peritoneal cavity but have been shown to
traffic to the pancreas prior to the onset of type 1 diabetes in a
mouse model of the disease (Ryan et al., 2010). In the pancreas,
B-1 cells promote the infiltration of diabetogenic T cells by induc-
ing the pancreatic vasculature to express VCAM-1 (Ryan et al.,
2010), an integrin ligand that supports T cell extravasation. Thus
the combined actions of MZ B cells and B-1 cells may be a key
factor in the activation of diabetogenic T cells and their ability to
infiltrate the pancreas, where they orchestrate the destruction of
insulin-producing islet cells.
The role of innate-like B cells in autoimmune diseases in
humans has yet to be fully explored because the equivalent cell
populations have beenmore difficult to identify. A CD27+ human
B-cell subset has been likened to murine MZ B cells in that
these cells can generate rapid T-independent antibody responses
against the carbohydrate capsules of pathogenic Gram-positive
bacteria. However, unlike murine MZ B cells that are localized
mainly to the spleen and express an “innate” germ-line encoded
Ig repertoire, CD27+ human B cells circulate and their Ig reper-
toire appears to have undergone antigen-independent somatic
hypermutation that may be similar to the way that the B cell Ig
repertoire is generated in sheep and other species (Weill et al.,
2009). These cells may therefore represent an innate-like B-cell
population that does not have an equivalent in the mouse. It is
not known whether their Ig repertoire is skewed towards self-
reactivity or if they contribute to autoimmunity. In contrast,
two distinct subpopulations of human B-1 cells can be distin-
guished by surface markers and transcriptome profile and a recent
report has shown that the CD11b+ human B-1 subset can acti-
vate T cells and is dramatically increased in SLE patients (Griffin
and Rothstein, 2011). The identification of these subsets will
undoubtedly lead to further studies of their functions and their
potential roles in autoimmunity.
TARGETING B CELLS TO TREAT AUTOIMMUNITY
The multiple mechanisms by which B cells contribute to chronic
inflammatory autoimmune diseases suggested that B cell deple-
tion could be an effective approach for treating these diseases.
Indeed, rituximab, a B cell-depleting anti-CD20 monoclonal
antibody that was first developed for the treatment of B-cell
malignancies, is now a standard therapy for rheumatoid arthritis
(Edwards and Cambridge, 2006). B-cell depletion with mono-
clonal antibodies against B cell-specific membrane proteins such
as CD20 and CD22 is also being considered as a treatment for
a variety of other B cell-mediated autoimmune diseases (Kazkaz
and Isenberg, 2004; Fiorina et al., 2008; Chan and Carter, 2010).
The neutralization of BAFF, a cytokine that promotes the sur-
vival of B-2 and MZ B cells may also be a useful approach for
depleting autoreactive B cells. Patients with rheumatoid arthri-
tis (Baker, 2004) and SLE (Lebien and Tedder, 2008) exhibit
elevated serum levels of BAFF and mice overexpressing BAFF
develop SLE-like syndrome with expanded B-cell populations,
elevated levels of anti-DNA antibodies, and immune complex
deposition in the kidney (Mackay et al., 1999; Khare et al., 2000).
In NOD mice, in vivo neutralization of BAFF reduces the level
of autoantibodies against insulin, decreases the severity of islet
inflammation, and reduces the incidence of spontaneous type
1 diabetes (Zekavat et al., 2008). Although global B-cell deple-
tion holds promise as a treatment for autoimmunity, the strong
association between autoimmunity and the expansion of innate-
like B cells with inherent self-reactivity suggests that inhibiting
the activation and function of the human equivalents of MZ B
cells and B-1 cells may be an important consideration for effec-
tively treating B cell-mediated autoimmune diseases. In mouse
models of autoimmune disease, there is evidence suggesting that
selectively targeting innate-like B cell populations can reduce dis-
ease incidence and progression. For example, in (NZB×NZW)F1
mice, which spontaneously develop autoimmune disease that is
very similar to SLE in humans, B-1 cell depletion delays disease
onset and reduces disease severity (Murakami et al., 1995), as
does depletion of B-1 and MZ B cells using B-cell super anti-
gens (Viau and Zouali, 2005). Similarly, as mentioned above, the
somewhat-selective depletion of MZ B cells reduces disease inci-
dence in a mouse model of type 1 diabetes (Noorchashm et al.,
1999b). Thus, targeting MZ and B-1 B cells could be a useful
approach for treating B cell-mediated autoimmune inflammatory
diseases.
TARGETING PI3Kδ TO TREAT AUTOIMMUNITY
Although a number of different approaches have been used to
treat autoimmune diseases, there are currently no curative ther-
apies and it appears that a combination of approaches may be
needed to provide effective and long-term protection from dis-
ease progression. In the context of treating type 1 diabetes, Luo
et al. (2010) have provided a critical analysis of past and cur-
rent strategies for treating autoimmunity by targeting immune
cells. In particular, agents that deplete B cells (e.g., the anti-CD20
monoclonal antibody rituximab) are now being investigated as
therapies for B cell-mediated autoimmune diseases. Mouse mod-
els of disease first showed the potential of this approach. The
incidence of spontaneous autoimmune diabetes in NOD mice
can be reduced by depleting B cells with anti-IgM-specific anti-
bodies (Noorchashm et al., 1997), antibodies to CD20 (Hu et al.,
2007; Xiu et al., 2008), anti-CD22 antibodies conjugated to a
cytotoxic agent (Fiorina et al., 2008), or a fusion protein that
sequesters the B-cell survival cytokine BAFF (Marino and Grey,
2008; Zekavat et al., 2008). Similar results have been obtained in
other mouse models of autoimmunity (Yu et al., 2008). B-cell
depletion with rituximab has now been tested in patients with
a variety of B cell-mediated autoimmune diseases, with some
success (Kazkaz and Isenberg, 2004; Martin and Chan, 2006;
Sanz et al., 2007; Pescovitz et al., 2009; Hegedus et al., 2011). In
a phase 2 clinical trial, rituximab treatment partially preserved
beta cell function in patients with type 1 diabetes (Pescovitz
et al., 2009). This incomplete efficacy could be due the variable
penetration of monoclonal antibodies into tissues, resulting in
poor depletion on innate-like B cell subsets (Gong et al., 2005;
Yu et al., 2008). Moreover, the use of antibodies for treating
chronic autoimmune diseases has been associated with infusion
site reactions and other adverse reactions caused by immune
complex formation (Vogel, 2010; El Fassi et al., 2011). A more
serious issue associated with B-cell depletion as a long-term
treatment approach for treating autoimmune diseases is chronic
immunosuppression (Luo et al., 2010), as well as the potential
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for eliminating beneficial B cells such as the recently identi-
fied “Bregs” that produce IL-10 and limit autoimmune reactions
(Mizoguchi and Bhan, 2006; Matsushita et al., 2008). Indeed, in
twomouse models of experimental autoimmune encephalomyeli-
tis, anti-CD20-induced B-cell depletion increased the severity
of the disease (Weber et al., 2010). The caveats associated with
antibody-mediated B-cell depletion strategies suggest that small
molecule inhibitors of B-cell function that are orally available,
have good tissue penetration, andwhose effects are reversible over
a short period of time (in contrast to causing long-term immuno-
suppression) may allow for “tunable” moderate levels of B cell
inhibition that can preserve beneficial B-cell functions while hav-
ing limited side effects over the prolonged treatment course for
chronic autoimmune diseases. Such B-cell inhibitors could be
useful for managing disease, but may also be useful as an adjunct
to rituximab, perhaps by reducing the frequency at which B-cell
depletion would need to be done.
Based on the findings described earlier, there are a number
of reasons why PI3Kδ is a very promising target for the treat-
ment of autoimmune inflammatory diseases, particularly those
in which B cells play a major role. By blocking B-cell migra-
tion, adhesion, survival, activation, and proliferation, inhibition
of p110δ activity would impair the ability of B cells to act as APCs
that activate autoreactive T cells, prevent their activation, and
reduces their secretion of autoantibodies and pro-inflammatory
cytokines. Moreover, innate-like B cells, which have been strongly
linked to autoimmunity, appear to be the most sensitive to loss of
PI3Kδ activity as MZ and B-1 cells are nearly absent in mice lack-
ing a functional p110δ gene. We have directly shown that PI3Kδ
inhibitors reduce the trafficking and activation of MZ and B-1
cells in vitro, as well as the localization of MZ B cells in mice
(Durand et al., 2009). Importantly, the restricted expression of
p110δ mainly in hematopoietic cells, the observation that B cells
are the cell type most impaired in mice lacking a functional ver-
sion of p110δ, and phase I clinical trial data showing that the
PI3Kδ inhibitor GS-1101 is safe and well-tolerated by patients
(Kahl et al., 2010) indicate that these compounds can be used to
modulate B-cell function in vivo without deleterious effects on
other cell types or significant side effects. As a proof-of-principle
that PI3Kδ inhibitors can inhibit B cell-mediated autoimmune
reactions in vivo, we showed that administering IC87114 to rats
reduces autoantibody production in a model of collagen-induced
arthritis (Durand et al., 2009).
PI3Kδ inhibitors such as IC87114 have now been shown
to reduce the incidence and severity of autoimmune arthri-
tis (Randis et al., 2008), asthma (Lee et al., 2006; Park et al.,
2010), experimental autoimmune encephalomyelitis (Haylock-
Jacobs et al., 2011), and SLE (Maxwell et al., 2012) in mouse
models. Our current work suggests that oral administration of
IC87114 opposes the progression of autoimmune diabetes in
NOD mice. The ability of PI3Kδ inhibitors to reduce the sever-
ity of these inflammatory diseases may be due not only to
their actions on innate-like B cells, but also to inhibitory effects
on other immune cells that contribute to autoimmune disease
(Fung-Leung, 2011). IC87114 inhibits the trafficking of neu-
trophils into inflamed tissues (Puri et al., 2004) and prevents the
activation of mast cells (Ali et al., 2004, 2008). PI3Kδ also plays
an important role in TCR-induced T-cell activation (Okkenhaug
et al., 2002, 2006) and IC87114 treatment inhibits TCR-induced
cytokine production by both naïve and memory human T cells
in vitro (Soond et al., 2010). In particular, p110δ signaling is
important for IL-17 production by bothmouse and human T cells
(Park et al., 2010; Soond et al., 2010; Haylock-Jacobs et al., 2011).
IL-17-producing TH17 cells have been implicated in a number of
autoimmune diseases (Jain et al., 2008; Emamaullee et al., 2009;
Crome et al., 2010). Finally, PI3Kδ mediates the TCR-induced
downregulation of CD62L (Sinclair et al., 2008), which is required
for the trafficking of activated T cells into tissues. The broad
spectrum of action against cells that contribute to autoimmune
processes, combined with the limited expression of p110δ in non-
hematopoietic tissues, suggests that PI3Kδ inhibitors could have
an excellent therapeutic index for the treatment of autoimmune
diseases.
Providing a further rationale for the use of PI3Kδ inhibitors
to treat autoimmune disease is the recent finding that enhanced
PI3Kδ activity is associated with autoimmunity in humans
(Suarez-Fueyo et al., 2011). PI3Kδ activity is significantly
increased compared to normal individuals in T cells from ∼70%
of SLE patients, and this difference is greatest in patients with
active disease. Consistent with a role for PI3K in promoting cell
survival, SLE patients exhibit an expanded population of CD4+
memory T cells, as well as defective activation-induced cell death
(AICD) of T cells, a defect that can be corrected in vitro by phar-
macological inhibition of p110δ with IC87114. AICD normally
limits the expansion of activated T cells and terminates immune
responses. Defects in AICD, for example in mice or humans with
loss-of-function mutations in Fas or FasL, are strongly correlated
with autoimmunity. This suggests that excessive activation of
PI3Kδ could contribute to the T cell dysregulation associated with
SLE. In this case, PI3Kδ inhibitors may be useful for treating SLE,
for which there is currently no effective cure or treatment. The
basis for the excessive PI3Kδ activity in SLE patients is not known
nor is it known whether aberrant PI3Kδ activity is associated with
other autoimmune diseases.
For treating autoimmune diseases, the therapeutic effects of
inhibiting PI3Kδ could potentially be enhanced by simultaneously
inhibiting PI3Kγ (Rommel et al., 2007). In addition to participat-
ing in the activation of T cells through the TCR, PI3Kγ signaling
is essential for neutrophils andmacrophages to invade tissues and
produce inflammatorymediators (Hirsch et al., 2000; Sasaki et al.,
2000; Alcazar et al., 2007). Like p110δ, p110γ is expressed mainly
in hematopoietic cells, such that selective inhibition of PI3K iso-
forms containing these catalytic subunits would have limited
toxicity on other cell types. Treatingmice with the PI3Kγ-selective
inhibitor AS605240 can reduce disease incidence and severity in
mouse models of rheumatoid arthritis, SLE, and type 1 diabetes
(Barber et al., 2005; Camps et al., 2005; Azzi et al., 2012), implicat-
ing PI3Kγ in these disease processes and suggesting that PI3Kγ,
like PI3Kδ, is a good therapeutic target for treating autoimmune
diseases. Abdi and colleagues (Azzi et al., 2012) provided several
mechanistic insights into how inhibition of PI3Kγ may prevent
the progression of autoimmune diabetes in NOD mice. Both
in vitro and in vivo studies showed that AS605240 inhibited the
expansion and effector functions (e.g., cytokine production) of
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autoreactive CD4+ T cells while expanding the number of regula-
tory T cells (Tregs), consistent with previous findings that PI3K
inhibition causes T cells to become Tregs instead of T-effector
cells (Haxhinasto et al., 2008; Sauer et al., 2008) This shift in the
Teff/Treg balance toward a more immunoregulatory or immuno-
suppressive state correlated with a delayed onset of diabetes in
NODmice. Importantly, similar to our preliminary findings with
the PI3Kδ inhibitor IC87114, treating NOD mice with the PI3Kγ
inhibitor when they first exhibited elevated blood glucose levels
provided sustained protection from progression to overt diabetes
in a number of animals (Azzi et al., 2012). These findings sug-
gest that combined inhibition of PI3Kγ and PI3Kδ could have
even greater efficacy in preventing diabetes progression. Recently
described dual inhibitors of PI3Kγ and PI3Kδ (Williams et al.,
2010) could therefore hold substantial promise as a therapeu-
tic approach for preventing disease progression in patients with
early-stage type 1 diabetes and perhaps other chronic autoim-
mune inflammatory diseases. However dual inhibition of PI3Kγ
and PI3Kδ may need to be carefully titrated, as loss of both
PI3Kγ and PI3Kδ activity in mice is associated with a shift in the
Th2/Th1 balance that leads to eosinophil-mediated multi-organ
inflammation (Ji et al., 2007).
The successful use of PI3Kγ/δ inhibitors to treat inflamma-
tory autoimmune diseases must take into account the need to
balance suppression of autoimmune responses with maintenance
of protective immunity as well as the potential for unexpected
pro-inflammatory consequences of PI3Kγ/δ inhibition, as has
been observed inmice. As mentioned above, eosinophil-mediated
inflammation is associated with the loss of both PI3Kγ and PI3Kδ
activity in mice (Ji et al., 2007). Moreover, loss of PI3Kδ activity
in mice greatly enhances isotype switching to IgE (Zhang et al.,
2008, 2012), which could lead to atopic reactions. It remains to be
seen whether these pro-inflammatory consequences of PI3Kγ/δ
inhibition occur in humans. The paradoxical effects of PI3Kδ
inhibition on Tregs, cells that play a critical role in limiting
autoimmune reactions, may also be an important factor to con-
sider. Inhibition of PI3Kδ activity has been reported to impair
Treg function, even though it promotes Treg development (Patton
et al., 2006; Sauer et al., 2008; Okkenhaug and Fruman, 2010).
Despite these caveats, phase I clinical trial data have shown that
the PI3Kδ inhibitor GS-1101 is safe and well-tolerated by patients
(Kahl et al., 2010). Thus optimized dosing regimens that cause
partial inhibition of PI3Kγ/δ may have the ability to substan-
tially inhibit autoimmune reactions without rendering protective
immune responses ineffective or causing significant unwanted
side effects.
PI3Kδ AS A TARGET FOR TREATING B-CELL
MALIGNANCIES
In addition to a key role for PI3Kδ in autoimmune inflamma-
tion, this pathway has emerged as a central mechanism underlying
the survival and expansion of various malignant B-cells. BCR sig-
naling is a central pathologic mechanism in B-cell malignancies,
including chronic lymphocytic leukemia (CLL), diffuse large B-
cell lymphoma (DLBCL) (Davis et al., 2010), and mantle cell
lymphoma (MCL). Comparative gene expression profiling data
demonstrate that BCR signaling is the most prominent pathway
activated in CLL cells isolated from lymphatic tissues (Herishanu
et al., 2011). Similarly,MCL cells display signs of constitutive acti-
vation of BCR (Rinaldi et al., 2006; Cecconi et al., 2008; Pighi
et al., 2011) and PI3K signaling (Martinez et al., 2003; Rizzatti
et al., 2005) in the absence of activating mutations. The role
of BCR-induced PI3K signaling in promoting the survival of
malignant B cells, combined with the fact that PI3Kδ is the pre-
dominant PI3K isoform involved in BCR signaling, make this
PI3K isoform a very promising target for the treatment of B-cell
cancers. Substantial progress, both preclinical and clinical, has
been made with GS-1101 (CAL-101), a selective inhibitor of the
PI3Kδ pathway. The importance of the PI3Kδ pathway in B cells,
as well as the initial development of GS-1101 as a treatment for
B-cell malignancies, has been reviewed recently by Fruman and
Rommel (2011).
ROLE OF PI3Kδ SIGNALING IN B-CELL MALIGNANCIES
The potential role of excessive PI3K signaling in the develop-
ment of B-cell malignancies was initially reported by Borlado
et al. (2000), who showed that mice expressing a constitutively
active form of PI3K develop infiltrating lymphoproliferative dis-
orders as well as autoimmune disease. There is now mounting
evidence for the importance of PI3K signaling in B-cell malignan-
cies. Uddin et al. (2006) demonstrated the constitutive activation
of the PI3K pathway in several DLBCL cell lines, importantly,
in primary cells from the majority of patients with DLBCL.
Constitutive activation of the PI3K pathway, as measured by ele-
vated levels of phospho-Akt, has also been demonstrated in MCL
cell lines and in primary cells from patients with MCL (Rudelius
et al., 2006). PI3K activation has also been observed in follicular
lymphoma (FL), mediastinal DLBCL, and Hodgkin’s lymphoma
(Renne et al., 2007; Garcia-Martinez et al., 2011). More recently, a
role for the PI3Kδ isoform in the pathophysiology of B-cell malig-
nancies has emerged. Several experiments have shown that there
is excessive p110δ activity in malignant lymphoid cells. Herman
et al. (2010) showed that there were significantly higher levels of
PI3K p110δ activity in primary cells from patients with CLL than
in normal hematopoietic cells. Similarly, PI3K p110δ is hyperac-
tivated in plasma cell myeloma (PCM) cell lines and malignant
cells from patients with PCM (Ikeda et al., 2010). Excessive PI3Kδ
activity has also been observed in cell lines and primary cells from
patients with Hodgkin’s lymphoma (Meadows et al., 2012).
The development of GS-1101, a potent and selective inhibitor
of PI3K p110δ, has enhanced our understanding of the role
of p110δ in B-cell malignancies. GS-1101 (5-Fluoro-3-phenyl-
2-[(S)-1-(9H-purin-6-ylamino)-propyl]-3H-quinazolin-4-one)
inhibits PI3K p110δ with an IC50 value of 2.5 nM in vitro whereas
its IC50 values for the p110α, p110β and p110γ subunits are 820,
565 and 89 nM, respectively (Lannutti et al., 2011). GS-1101 also
shows a greater selectivity for inhibition of p110δ than for mTOR
and other related kinases, and demonstrates high selectivity for
p110δ when tested against a panel of more than 400 diverse
kinases (Lannutti et al., 2011). Additionally, in isoform-specific
cell-based assays, GS-1101 blocks PI3Kδ-dependent responses
at concentrations that are >240-fold lower than those required
to inhibit responses that are dependent on other PI3K isoforms
(Lannutti et al., 2011). In addition to GS-1101, several other
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PI3Kδ inhibitors are now in clinical trials and many more are
in preclinical development, as described in a recent review
(Norman, 2011).
The mechanism of action of GS-1101 has been studied in
cell lines and primary patient samples representing diverse B-cell
malignancies including CLL, DLBCL, and multiple myeloma
(MM) (Herman et al., 2010; Ikeda et al., 2010; Hoellenriegel
et al., 2011; Lannutti et al., 2011). Primary cells derived from CLL
patients have high levels of p110δ and treating these cells with
low micromolar concentrations of GS-1101 promotes apoptosis
through caspase activation (Herman et al., 2010). This cytotoxic
effect of GS-1101 is independent of the IgVH mutational sta-
tus of the cells as well as interphase cytogenetic abnormalities,
the common prognostic factors associated with poor response
to therapy in CLL. Interestingly, GS-1101 inhibits not only con-
stitutive PI3K signaling in these cells but also antagonizes CLL
cell survival by blocking the protective effect of CD40-ligand
(CD40L) and microenvironmental stimuli (Herman et al., 2010).
In particular, the cytokines BAFF and TNFα enhance the sur-
vival of primary CLL cells in vitro but this effect is attenuated
by submicromolar concentrations of GS-1101 (Herman et al.,
2010). Similarly, the survival advantage conferred to CLL cells
by growth on fibronectin or stromal cell layers is reversed by
GS-1101 (Herman et al., 2010).
More recent work demonstrated that GS-1101 completely
blocks survival signals mediated by BCR engagement and sig-
nificantly reduces survival of CLL cells cultured on specialized
nurse-like cells (NLC) derived from peripheral blood monocytes
(Hoellenriegel et al., 2011). Furthermore, GS-1101 decreases the
secretion of survival-associated chemokines by both the CLL
cells (CCL2, CCL3) and stromal cells (CXCL13) in a co-culture
model. The co-culture of CLL and NLC triggers the release
of additional survival factors (CCL7, CCL17, CCL22, soluble
CD40L, IL-6, and TNFα) whose secretion is also reduced by GS-
1101. Additionally, GS-1101 inhibits CLL cell chemotaxis toward
CXCL12 and CXCL13. These chemokines are commonly present
in the B-cell follicles of lymph nodes and chemoattract CLL cells
to this protective microenvironment. Together these observa-
tions suggest that PI3Kδ inhibition with GS-1101 can antagonize
intrinsic survival signals and also block survival signals provided
by extrinsic factors in the tumor microenvironment.
PI3Kδ plays an essential role in PCM cell function (Ikeda
et al., 2010). All PCM cell lines express p110δ and treatment with
micromolar concentrations of GS-1101 inhibits the constitutive
phosphorylation of Akt observed in these cells. This correlates
with caspase-dependent apoptosis in p110δ-positive PCM cells,
with minimal cytotoxicity in p110δ-negative cells (Ikeda et al.,
2010). IL-6 and IGF-1, which are present in the bone marrow
(BM) microenvironment, promote MM cell proliferation and
survival. Importantly, the cytotoxic effect of GS-1101 on PCM
cells was not diminished in the presence of IL-6 and IGF-1,
suggesting that GS-1101 can overcome the protective effects of
these cytokines within the BM milieu. GS-1101 also exhibits an
inhibitory effect on PCM cells in the presence of BM stromal
cells (BMSCs), and inhibited the growth, cytokine production,
and Akt phosphorylation that are induced in PCM cells by their
association with BMSCs (Ikeda et al., 2010).
PI3K p110δ INHIBITION WITH GS-1101 IN PATIENTSWITH
B-CELL MALIGNANCIES
GS-1101 was the first selective inhibitor of PI3Kδ to enter clin-
ical testing for various B-cell malignancies including CLL, non-
Hodgkin lymphoma (NHL), acute myeloid leukemia (AML),
DLBCL, and MM. Remarkably, treatment with GS-1101 as a sin-
gle agent provided durable remissions to a significant percentage
of patients with CLL and certain subtypes of NHL (Sharman
et al., 2011). Most of these patients had relapsed from multiple
other treatment regimens yet responded to the p110δ inhibitor.
GS-1101 also showed impressive efficacy when combined with
standard-of-care agents (e.g., rituximab, bendamustine, and flu-
darabine) for indolent NHL (iNHL) and CLL. Currently GS-1101
has advanced to phase 3 clinical testing in CLL as a single agent or
in combination with rituximab and bendamustine (clinical trial
identifiers: NCT01569295, NCT01539291, and NCT01539512).
In addition, an ongoing phase 2 clinical study is evaluating the
efficacy and safety of GS-1101 in patients with relapsed or refrac-
tory Hodgkin lymphoma (clinical trial identifier: NCT01393106).
Althoughmost of the data have not yet been published in peer-
reviewed journals, some of the clinical data for trials involving
GS-1101 have been presented at meetings over the past few years
and described in abstracts of the conference proceedings (Flinn
et al., 2009a,b,c; Brown et al., 2010; Flinn et al., 2010; Furman
et al., 2010a; Kahl et al., 2010; de Vos et al., 2011; Kahl et al., 2011;
Leonard et al., 2011; Sharman et al., 2011). Most recently, Miller
and colleagues (Sharman et al., 2011) reported on a phase I study
of GS-1101 as single agent and in combination with rituximab
and/or bendamustine in patients with relapsed/refractory CLL
(clinical trial identifiers: NCT00710528 andNCT01088048). Data
were presented from 55 patients with CLL who were administered
GS-1101 monotherapy and 54 patients who received GS-1101-
based combination therapies. GS-1101 as single agent or as part
of a combination therapy caused lymph node shrinkage in a large
majority of CLL patients (>79%) across all dose levels. Nodal size
changes occurred in two phases: a steep initial reduction (>50%
reduction by week 8) that was followed by a persistent continu-
ing decline over several months. The extent and kinetics of the
nodal responses were similar in patients treated with single-agent
GS-1101 or with combination therapies. A significant percent-
age of patients showed durable responses (approximately 25%
overall response rate) with single-agent GS-1101 and remained
on study for many cycles of treatment. GS-1101-based combi-
nations substantially increased the overall response rate to 81%
compared to single-agent therapy. The median progression-free
survival in patients on GS-1101 monotherapy was >12 months
and the median progression-free survival for any combination
therapy has not yet been reached but has exceeded 12 months.
The initial lymph node reduction observed in the majority of
CLL patients treated with single-agent GS-1101 was accompa-
nied by a transient elevation in circulating lymphocyte counts
(Sharman et al., 2011), a phenomenon known as lymphocyto-
sis. This lymphocytosis resolved over several months of contin-
ued GS-1101 treatment. This redistribution of CLL cells from
the tissues into the blood is likely the result of lymphocytes
being released from lymphoid tissue microenvironments or fail-
ing to home from the blood into lymph nodes, resulting in the
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eventual death of tumor cells that are prevented by GS-1101 from
accessing the supportive microenvironment of the lymph nodes.
Importantly, the pattern and extent of lymphocytosis in CLL
patients were altered by combination therapy. The combination
of GS-1101 with rituximab or fludarabine led to a shorter dura-
tion of lymphocytosis while the combination with bendamustine
largely eliminated the increase in circulating lymphocyte counts
(Sharman et al., 2011).
The CLL patients treated with GS-1101 monotherapy and
combination therapy also showed significantly reduced plasma
levels of the chemokines CXCL13, CCL3, CCL4 and cytokine
TNFα after 28 days of treatment compared with pretreat-
ment measurements, further suggesting disruption of the CLL
microenvironment by GS-1101 (Hoellenriegel et al., 2011;
Sharman et al., 2011). As described earlier, previous studies
demonstrated an important role for PI3Kδ in B-cell adhesion,
migration, and homing to lymphatic tissues (Reif et al., 2004;
Durand et al., 2009). B cells from PI3K p110δ knockout mice
respond poorly to CXCL13, and exhibit reduced homing to lym-
phatic tissues in adoptive transfer experiments (Reif et al., 2004).
PI3Kδ activity is also required for chemotactic and adhesive
signals that mediate the localization of B cells in lymphoid tis-
sue, as indicated by the ability of in vitro IC87114 treatment
to inhibit B cell chemotaxis toward CXCL13 and S1P as well
as CXCL13-stimulated adhesion to ICAM-1, which is mediated
by the LFA-1-integrin (Durand et al., 2009). Consistent with
this, treating mice with IC87114, a selective PI3Kδ inhibitor
(Sadhu et al., 2003b), disrupted the in vivo localization of MZ
B cells in mice (Durand et al., 2009). Indeed, the notable clin-
ical activity of GS-1101 in CLL is associated with mobilization
of CLL cells from tissues into the blood, which results in pro-
nounced lymph node shrinkage and transient lymphocytosis.
Thus GS-1101 displays a dual mechanism of action against CLL,
directly decreasing BCR-induced CLL cell survival (see above)
and inhibiting chemokine-dependent interactions that retain
CLL cells in survival-promoting tissue microenvironments. These
combined actions may account for the ability of this PI3Kδ
inhibitor to sensitize CLL cells to the current standard-of-care
agents. Similar effects have been observed with inhibitors of
the Syk, Btk, and mTOR kinases, which also function in both
chemokine receptor and BCR signaling pathways (Friedberg et al.,
2010; Zent et al., 2010; Burger, 2012; de Rooij et al., 2012). The
common mechanism underlying the antitumor activity of these
kinase inhibitors that are active against CLLmay be their ability to
inhibit multifunctional signaling pathways that control leukemia
cell survival, adhesion, migration, and homing.
Similar promising results have been obtained in a phase 1
study (de Vos et al., 2011) of GS-1101 as a single agent and in
combination with rituximab and/or bendamustine for treatment
of patients with relapsing/remitting iNHL (clinical trial identi-
fiers: NCT00710528 and NCT01088048). Data were presented
from 63 patients with iNHL on GS-1101 monotherapy and 52
patients on GS-1101-based combination therapies representing
all four subtypes of iNHL: follicular, small lymphocytic, lym-
phoplasmacytic, and MZ, with FL being the most common in
all treatment arms. GS-1101 as single agent or as combination
therapy caused substantial tumor regression in a large majority of
patients with indolent NHL and across all dose levels. The over-
all response rate for GS-1101 monotherapy was 38% across all
dose levels and 59% at doses≥ 100mg twice daily. GS-1101-based
combinations substantially increased the overall response rate to
83% compared to single-agent therapy. Furthermore, complete
remission was achieved in 15–25% of patients on GS-1101-based
combination therapies. Similar to clinical data in CLL, both GS-
1101 monotherapy and combination therapy were associated
with durable tumor control with the median progression-free
survival in patients receiving GS-1101 monotherapy at doses ≥
100mg twice daily, receiving any combination therapy, was >12
months.
Consistent with observations in CLL patients, treatment of
iNHL patients with single-agent GS-1101 or combinations signif-
icantly decreased plasma levels of CCL17, CCL22, CXCL13, and
TNFα. However, unlike the biphasic nodal response and transient
lymphocytosis observed in CLL patients treated with GS-1101
monotherapy, iNHL patients show profound and rapid reduc-
tions in lymph nodes. The lymphocytosis has not been reported
in patients with iNHL treated with single-agent GS-1101 or with
combination therapies, suggesting that redistribution of cells to
the periphery may not be a critical mechanism of antitumor
activity of GS-1101 in iNHL. This is also consistent with the
observation that iNHL cells are not generally found in circula-
tion; hence, they are likely being cleared in the tissue sites rather
than in the periphery.
GS-1101 has also been tested as a single agent treatment in
a small number of patients (9–11 each) with MM, AML, and
DLBCL malignancies. However, as reported in conference pro-
ceeding abstracts, it has not shown the same level of efficacy as
for CLL and NHL (Flinn et al., 2009a; Furman et al., 2010b; Kahl
et al., 2010). Because the effects of GS-1101 on the redistribu-
tion of malignant cells and on plasma chemokine and cytokine
levels in these patients has not been reported, it is not known
if the lack of efficacy was due to insufficient inhibition of the
PI3K pathway or to protective microenvironmental signals in
these malignancies. Whether GS-1101 treatment would make
these malignant cells more susceptible to other standard-of-care
treatments remains to be determined.
An important consideration for therapeutics that target signal-
ing pathways that are essential for the survival and dissemination
of malignant lymphocytes is whether they will also suppress ben-
eficial anti-tumor immunity. Several studies have reported that
PI3Kδ is required for the function of immune cells that could
influence the immune response to tumor cells. GS-1101 strongly
suppresses cytokine production by human T cells (Herman et al.,
2010). Moreover, inhibition of PI3Kδ may also have detrimental
effects on tumor immunosurveillance by NK cells and cytotoxic
T lymphocytes (CTL). PI3Kδ activity is important for NK cell
activation and function (Kim et al., 2007; Saudemont et al., 2007)
and for induction of both the perforin-granzyme and death-
receptor pathways of CTL-mediated tumor cell killing (Putz et al.,
2012). In addition, Tregs play a key role in restraining immune
responses including anti-tumor responses but the net effect of
PI3Kδ inhibition on Tregs is still unclear. Loss of PI3Kδ activ-
ity promotes the differentiation of T cells into Tregs but can
also inhibit Treg function (Patton et al., 2006; Sauer et al., 2008;
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Okkenhaug and Fruman, 2010). Thus determining how to
balance inhibition of malignant cell survival with mainte-
nance of anti-tumor immunity will be the key to treatment
success.
CONCLUSIONS
Recent data has demonstrated that the PI3Kδ pathway is a
critical signaling circuit in B cells and plays a key role in
autoimmune inflammation as well as some lymphoid malig-
nancies. This pathway is hyperactivated in various B-cell malig-
nancies and its inhibition with PI3Kδ-targeted compound has
achieved promising clinical responses in patients with CLL,
iNHL, and other B-cell neoplasia. The PI3Kδ inhibitor GS-
1101 appears to antagonize both intrinsic and extrinsic cell
survival signals, decreases the survival of CLL cells directly,
and abrogates cellular interactions between CLL cells and com-
ponents of the tissue microenvironment that normally sus-
tain leukemia and lymphoma cells in a protective niche.
Ongoing clinical studies are further characterizing the risks
and benefits of long-term PI3Kδ inhibition. Nevertheless, the
initial trials suggest that GS-1101 has significant potential
both as a single agent and in combination with bendamus-
tine and rituximab for the treatment of CLL and iNHL
(clinical trial identifiers: NCT01569295, NCT01539512, and
NCT01539291). Ongoing clinical studies are also evaluating GS-
1101 to potentially expand its utility in additional B-cell malig-
nancies such as Hodgkin’s lymphoma (clinical trial identifier:
NCT01393106).
The PI3Kδ pathway is also constitutively activated in vari-
ous inflammatory conditions and pharmacological inhibition or
genetic inactivation of this pathway has demonstrated efficacy in
several preclinical models of inflammation. Clinical studies are
now evaluating the potential of PI3Kδ inhibitors for the treatment
of a variety of inflammatory diseases (clinical trial identifiers:
NCT00836914 and NCT01462617). In addition to B-cell inhi-
bition, PI3Kδ inhibitors are also likely to significantly impact
differentiation, migration, and cytokine production by T cells
as well as the degranulation of mast cells, suggesting that these
agents may be effective beyond autoimmune diseases. As is the
case for all immunosuppressive agents, a balance between sup-
pressing autoimmunity and maintaining protective immunity
needs to be established. Orally available small molecule inhibitors
that have a short in vivo half-life would allow this balance to be
adjusted in a continual manner.
In conclusion, PI3Kδ plays a major role in both B-cell-
mediated inflammation and B-cell malignancies, and PI3Kδ
inhibitors therefore represent a promising therapeutic approach
to treating these diseases.
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